Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market.

MANews-(C)2009-2021

US-based clinical research organization Emmes has acquired German CRO Institut Dr. Schauerte, the company said.

Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-up studies.

It has conducted more than 400 studies across a range of therapeutic areas.

This is the third acquisition for Emmes in the last year, having previously purchased Neox, headquartered in the Czech Republic, in December 2020 and UK-based Orphan Reach in May 2021.

The acquisition of Institut Dr. Schauerte augments Emmes' global reach by expanding the company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.

With Institut Dr. Schauerte, Emmes now has more than 1,200 employees.

Institut Dr. Schauerte's clinical trial operations have been conducted in more than 20 countries, and the company has seen accelerating revenues from post-approval non-interventional studies.

RWE and Real World Data have become increasingly important in improving patient care and influencing product development and lifecycle management decisions for drug, device and diagnostic manufacturers.

Institut Dr. Schauerte also expands Emmes' technology product line with its ClinDoc tool, a secure, intuitive CFR21 Part 11 compliant Electronic Data Capture solution.

It includes multi-language capabilities...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT